Patents by Inventor Jens C. Norrild

Jens C. Norrild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dipeptide comprising a non-proteogenic amino acid
    Patent number: 10954267
    Abstract: Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: March 23, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Caspar Christensen, Michael Raunkjaer, Rune Severinsen, Jens C. Norrild
  • Dipeptide Comprising a Non-Proteogenic Amino Acid
    Publication number: 20190002496
    Abstract: Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids.
    Type: Application
    Filed: July 5, 2018
    Publication date: January 3, 2019
    Inventors: Caspar Christensen, Michael Raunkjaer, Rune Severinsen, Jens C. Norrild
  • Dipeptide Comprising a Non-Proteogenic Amino Acid
    Publication number: 20170096450
    Abstract: Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Inventors: Caspar Christensen, Michael Raunkjaer, Rune Severinsen, Jens C. Norrild
  • GLP-1 prodrugs
    Patent number: 9452225
    Abstract: The invention relates to a GLP-1 prodrug of the general formula I: R1-(NHXaa1)-Xaa2-(OHis)-(GLP-1 peptide) (Formula I), wherein GLP-1 peptide is GLP-1(8-37) (SEQ ID NO: 1) or an analog thereof having a maximum of nine amino acid changes as compared to GLP-1(8-37), R1 is lower alkyl, (NHXaa1) is an amino acid, Xaa2 is an amino acid, and (OHis) is a radical of imidazole-lactic acid; or a pharmaceutically acceptable salt, amide, or ester of the prodrug. The invention also relates to specific GLP-1 parent drugs of the general formula II: (HOHis)-(GLP-1 peptide) (Formula II), as well as specific intermediate products.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: September 27, 2016
    Assignee: Novo Nordisk A/S
    Inventor: Jens C. Norrild
  • GLP-1 PRODRUGS
    Publication number: 20150045281
    Abstract: The invention relates to a GLP-1 prodrug of the general formula I: R1-(NHXaa1)-Xaa2-(OHis)-(GLP-1 peptide) (Formula I), wherein GLP-1 peptide is GLP-1(8-37) (SEQ ID NO: 1) or an analogue thereof having a maximum of nine amino acid changes as compared to GLP-1(8-37), R1 is lower alkyl, (NHXaa1) is an amino acid, Xaa2 is an amino acid, and (OHis) is a radical of imidazole-lactic acid; or a pharmaceutically acceptable salt, amide, or ester of the prodrug. The invention also relates to specific GLP-1 parent drugs of the general formula II: (HOHis)-(GLP-1 peptide) (Formula II), as well as specific intermediate products.
    Type: Application
    Filed: February 26, 2013
    Publication date: February 12, 2015
    Inventor: Jens C. Norrild
  • Dipeptide Comprising a Non-Proteogenic Amino Acid
    Publication number: 20140364587
    Abstract: Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids.
    Type: Application
    Filed: December 20, 2012
    Publication date: December 11, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Caspar Christensen, Michael Raunjær, Rune Severinsen, Jens C. Norrild